A novel combinatory treatment against a CDDP-resistant non-small cell lung cancer based on a Ruthenium(II)-cyclopentadienyl compound

The therapeutic approach to many solid tumors, including non-small cell lung cancer (NSCLC), is mainly based on the use of platinum-containing anticancer agents and is often characterized by acquired or intrinsic resistance to the drug. Therefore, the search for safer and more effective drugs is sti...

Descripció completa

Dades bibliogràfiques

Autors principals:	Iris C. Salaroglio, Denitsa Stefanova, Ricardo G. Teixeira, Nuno F.B. Oliveira, Amer Ahmed, Fabio Fusi, Virginia Tzankova, Yordan Yordanov, Miguel Machuqueiro, Simona Saponara, Andreia Valente, Chiara Riganti
Format:	Artigo
Idioma:	Inglês
Publicat:	Elsevier 2024-10-01
Col·lecció:	Pharmacological Research
Matèries:	Cisplatin resistance ruthenium-cyclopentadienyl non-small cell lung cancer biocompatibility cardiovascular toxicity
Accés en línia:	http://www.sciencedirect.com/science/article/pii/S1043661824002986
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!